A placebo controlled clinical trial on the efficacy of atorvastatin 20 mg daily in patients with bronchial hyper-responsiveness.

Phase 1

Recruiting

• Conditions: bronchial hyper-responsiveness; Respiratory - Asthma

• Registration Number: ACTRN12609000704291
• Lead Sponsor: Shahid Beheshti University, M.C.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-08-14
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients present with cough for more than 6 weeks.

Exclusion Criteria

Patients who had contraindication for methacoline challenge test (according to American Thoracic Society/European Respiratory Society -ATS/ERS- guideline 2006)/ patient with previous diagnosis of asthma/patients who suffer heart failure/ obvious paroxysmal nocturnal dyspnea (PND) or wheezing in physical exam.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Decrease in hyperresponsiveness in methacoline challenge test at Baseline and at 4-6 weeks[at Baseline and at 4-6 weeks from the start of the treatment]

Secondary Outcome Measures

Name	Time	Method
Decrease in cough (questionnaire) at Baseline and at 4-6 weeks from the start of the treatment[at Baseline and at 4-6 weeks from the start of the treatment];serum IgE (lab test) at Baseline and at 4-6 weeks from the start of the treatment.[at Baseline and at 4-6 weeks from the start of the treatment];blood eosinophilia (lab test) at Baseline and at 4-6 weeks from the start of the treatment[at Baseline and at 4-6 weeks from the start of the treatment]